Past Associate Editor
Dr. Tsao is a Professor in the Department of Thoracic/Head & Neck Medical Oncology at the University of Texas M.D. Anderson Cancer Center (MDACC). She is the Director of the Mesothelioma Program and the Director of the Thoracic Chemo-Radiation Program at MDACC. Dr. Tsao is a clinician scientist and an expert in the treatment of patients with both thoracic and head and neck cancers. She conducts both clinical and translational laboratory research and focuses on identifying new therapeutic targets and developing novel strategies for the treatment of aerodigestive cancers and mesothelioma. Her research concentrates on individualizing cancer therapy through understanding the molecular mechanisms of disease. Dr. Tsao serves on the SWOG Mesothelioma Steering Committee, SWOG Lung Executive Committee, IASLC Communications Committee, and RTOG Lung Executive Committee, and is on the Scientific Board of the American Radium Society. Dr. Tsao was a member of the board of NEJM Journal Watch Oncology and Hematology from 2013 until 2021.
Information about this editor was up to date at the time of her last affiliation with NEJM Journal Watch.
Genentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology
Medimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb